Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 9, 2000, Pages 950-956

  Varis, K ^a   Sipponen, P ^a   Laxen, F ^a   Samloff, I M ^a   Huttunen, J K ^a   Taylor, P R ^a   Heinonen, O P ^a   Albanes, D ^a   Sande, N ^a   Virtamo, J ^a   Harkonen, M ^a   Varis, K S ^a   Edwards, B K ^a   Greenwald, P ^a   Butrum, R ^a   Pikkarainen, P ^a   Karvonen, A L ^a   Toivanen, E ^a   Antila, S ^a   Krekela, I ^a   Aarynen, M ^a   Hakkiluoto, A ^a   Aalto, K ^a   Lindstrom, C J ^a   Tunturi Hihnala, H ^a   Lampinen, M ^a   Haapakoski, J ^a   Mutikainen, J ^a   Tarpila, S ^a   Sivula, A ^a   Brown B W , Jr ^a   DeMets, D L ^a   Lewin, K ^a   Bilhuber, W ^a   Salkeld, R ^a   Schalch, W ^a   Speiser, R ^a   more..

^a JORVI HOSPITAL   (Finland)

Author keywords

Atrophic gastritis; Cancer prevention; Dysplasia; Gastric cancer; Pepsinogen

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; PEPSINOGEN I;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PREVENTION; CANCER RISK; DIAGNOSTIC VALUE; DYSPLASIA; EARLY DIAGNOSIS; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0033819248     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750023011     Document Type: Article

References (37)

1. Trends in cancer mortality in 15 industrialised countries, 1969-1986
2. Surveillance of pernicious anaemia
3. Gastric cancer risk in chronic atrophic gastritis: Statistical calculations of cross-sectional data
4. An appraisal of tests for severe atrophic gastritis in relatives of patients with pernicious anemia
5. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
6. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: Design, methods, participant characteristics, and compliance
7. Gastric cancer and premalignant lesions in atrophic gastritis: A controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene
8. Pepsinogens I and II. Purification from gastric mucosa and radioimmunoassay in serum
9. Serum pepsinogen I and the state of gastric mucosa in an Estonian population sample
10. The Sydney system: Histological division
11. Histopathology of gastric dysplasias
12. Precancerous conditions and epithelial dysplasia in the stomach
13. A classification of gastric dysplasia
14. Gastric dysplasia: Significance and pathologic criteria
15. Gastric dysplasia
16. Serum pepsinogen I and serum gastrin in screening of atrophic pangastritis with high risk of gastric cancer
17. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: Development of a biomarker strategy for gastric atrophy in high risk groups
18. The ratio of pepsinogen A to pepsinogen C: A sensitive test for atrophic gastritis
19. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: A follow-up study
20. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients: A prospective study
21. High grade dysplasia of the gastric mucosa: Marker for gastric carcinoma
22. Gastric dysplasia. A follow-up study
23. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists
24. Gastroskopia hyodyllinen tutkimus terveyskeskuksessa
25. Etiology of dyspepsia: Four hundred unselected consecutive patients in general practice
26. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects
27. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer
28. The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography
29. Serum pepsinogens as a screening test of extensive chronic gastritis
30. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens
31. Serum pepsinogen in screening for gastric cancer
32. Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distribution of levels of serum pepsinogen I, II and of PG1/PGII ratios in a gastric cancer case-control study
33. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research group on prevention of gastric carcinoma among young adults
34. Pepsinogen A/pepsinogen C or pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer
35. Serum pepsinogen I as a predictor of stomach cancer
36. Evaluation of pepsinogen A and gastrin-17 as markers of gastric cancer and high-risk pathologic conditions